Data as of 3:59pm ET
| -0.03 / -1.95%|
The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +363.58% increase from the last price of 1.51.
The current consensus among 3 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.